Traditional solid-phase oligonucleotide synthesis is hitting its limits as demand for RNA therapeutics surges. Enzyme-enabled RNA synthesis offers a scalable, sustainable alternative — and leading ...
Johnson & Johnson’s Tecvayli (teclistamab-cqyv), used in combination with daratumumab to treat relapsed or refractory multiple myeloma, has received FDA’s latest national priority voucher, becoming ...
IDMP standards aim to improve medicinal product data management but have faced delays, limiting their benefits for the life ...
George Tidmarsh and Vinay Prasad have taken leadership roles at CDER and CBER, respectively, impacting FDA's drug and ...
The CNPV pilot program approved its first drug, an amoxicillin-clavulanate potassium antibiotic, in two months, enhancing domestic manufacturing and national security. Augmentin XR, combining ...
The European Union (EU) reform establishes a regulatory data and market protection period of eight years, capped at 11 years ...
The agency is approaching the new overhaul as a chance to reshape drug regulations in the European Union.
The EU pharmaceutical reform aims to improve drug accessibility, affordability, and innovation, addressing market protection and antimicrobial resistance. Co-legislators in Europe have reached a ...
Indivumed, of Hamburg, Germany, is no stranger to cancer-centered collaborations; in August 2021, the company announced a ...
Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience ...
Sanner, a company that offers sustainable packaging products and contract development and manufacturing services, announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results